Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.62 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.53 |
| ▸ | HPGDS | O60760 | 2/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29132103 | 0.97 | CRBN (0.59) | CRBNDDB1HPGDSARGPR119 | |
| SCHEMBL29927587 | 0.97 | CRBN (0.59) | CRBNDDB1HPGDSARGPR119 | |
| SCHEMBL29132148 | 0.96 | CRBN (0.59) | CRBNDDB1HPGDSARALDH1A1 | |
| SCHEMBL29927550 | 0.96 | CRBN (0.59) | CRBNDDB1HPGDSARALDH1A1 | |
| SCHEMBL26125102 | 0.95 | CRBN (0.60) | CRBNDDB1HPGDSARALDH1A1 | |
| SCHEMBL31653793 | 0.95 | CRBN (0.60) | CRBNDDB1HPGDSARALDH1A1 | |
| SCHEMBL24481043 | 0.93 | CRBN (0.64) | CRBNDDB1HPGDSGPR119 | |
| SCHEMBL20046281 | 0.92 | CRBN (0.67) | CRBNDDB1HPGDSALDH1A1CHRM2 | |
| SCHEMBL22297514 | 0.92 | CRBN (0.67) | CRBNDDB1HPGDSALDH1A1CHRM2 | |
| SCHEMBL29629059 | 0.92 | CRBN (0.67) | CRBNDDB1HPGDSALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2024152247-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS G12D VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS , INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024054625-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS G12D VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4308557-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117321046-A | Indazole-based compounds and related methods of use | 阿维纳斯企业公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-115397821-A | Bifunctional molecules containing an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220323457-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2022198112-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-4045496-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | Arvinas Operations, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021077010-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | ARVINAS OPERATIONS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | CRBN 3/4885DDB1 433/4885HPGDS 3994/4885 |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | CRBN 5/4885DDB1 205/4885HPGDS 1526/4885 |
| US-20220323457-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | CRBN 5/4885DDB1 205/4885HPGDS 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.